In the intervention group, the adverse effects were as follows: one participant developed both leukopenia and neutropenia; two developed thrombocytopenia; three experienced creatine kinase increases; four developed elevated ALT; and five subjects developed elevated AST. The gene discussed is GPT; the disease is neutropenia.